LB PHARMACEUTICALS INC
About LB PHARMACEUTICALS INC
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$25.2M
- Total assets
- $312.9M
- Market cap
- $818.1M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Operating expenses
- $30.4M
- Income tax
- $1.0K
- Net income
- -$25.2M
- EPS (basic)
- $-3.13
- EPS (diluted)
- $-3.13
Balance sheet
- Total assets
- $312.9M
- Current assets
- $308.4M
- Total liabilities
- $11.6M
- Current liabilities
- $7.4M
- Shareholders’ equity
- $301.3M
Cash flow
- Operating cash flow
- -$35.2M
- Investing cash flow
- -$39.9M
- Financing cash flow
- $302.6M
- Net cash flow
- $227.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $818.1M
- EPS (diluted)
- $-3.13
- Shares outstanding
- 27.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 11, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $25.2M.
- Trading 11% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review LB PHARMACEUTICALS INC.
Write a review
News about LB PHARMACEUTICALS INC
News & sentiment via Polygon.io
